Pfizer Investor Presentation — October 2020

Document content

Earnings Teleconference

Senior Vice President, Investor Relations 3Forward-Looking Statements and Non-GAAP Financial Information

l Our discussions during this conference call will include forward-looking statements about, among other things, our anticipated future operating and

financial performance, business plans and prospects, expectations for our product pipeline, in-line products and product candidates, including

anticipated regulatory submissions, data read-outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and

potential benefits, strategic reviews, capital allocation objectives, the benefits anticipated from the reorganization of our commercial operations in

2019, plans for and prospects of our acquisitions and other business development activities, including our proposed transaction with Mylan N.V.

(Mylan) to combine Upjohn and Mylan to create a new global pharmaceutical company and our transaction with GlaxoSmithKline plc which

combined our respective consumer healthcare businesses into a new consumer healthcare joint venture, our ability to successfully capitalize on

growth opportunities and prospects, manufacturing and product supply, our efforts to respond to COVID-19, including our investigational vaccine

candidate against SARS-CoV-2 and our investigational protease inhibitor, our expectations regarding the impact of COVID-19 on our business,

operations and financial results and plans relating to share repurchases and dividends that are subject to substantial risks and uncertainties that

could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to risks,

uncertainties and other factors that may cause actual results to differ materially from past results, future plans and projected future results.